To assess treatment patterns and outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line chemotherapy or antiandrogen therapy.
Patients initiating first-line antiandrogen therapy (abiraterone, enzalutamide) or chemotherapy (taxane) between October 2012 and September 2014 were retrospectively identified in the US Veterans Health Administration database. The impact of antiandrogen therapy vs chemotherapy on overall survival (OS) and time to discontinuation was assessed using Cox proportional hazard models, adjusting for prior androgen deprivation therapy (ADT) duration and available prognostic factors.
Results
Overall, 1445 patients were evaluable, of whom 1108 received antiandrogen therapy and 337 received chemotherapy (docetaxel). On multivariable analysis and propensity score analysis, the OS times for antiandrogen therapy vs chemotherapy were not significantly different (hazard ratio [HR] 1.041, 95% confidence interval (CI) 0.853-1.270, P = 0.694, and HR 1.047, 95% CI 0.861-1.273, P = 0.644, respectively). Time to discontinuation was shorter for chemotherapy vs antiandrogen therapy (HR 2.339, 95% CI 1.969-2.779; P < 0.001). Prior ADT duration above the median was associated with longer OS (HR 0.566, 95% CI 0.464-0.690; P < 0.001) and time to discontinuation (HR 0.831, 95% CI 0.699-0.988; P = 0.036) in the antiandrogen therapy cohort and not the chemotherapy cohort, while prior ADT duration below the median was associated with higher prostate specific antigen (PSA) response rate in the chemotherapy vs antiandrogen therapy cohort (61.5% vs 51.1%; P = 0.024). The treatment-free interval after discontinuation was longer after first-line chemotherapy vs antiandrogen therapy (mean 53 vs 39 days; P = 0.030).
Introduction
Several new therapies for metastatic castration-resistant prostate cancer (mCRPC) have recently been introduced into the clinic, including chemotherapy and several novel antiandrogen therapies [1] . Each of these agents (docetaxel, cabazitaxel, abiraterone, enzalutamide) and other novel agents (radium-223, sipuleucel-T) has demonstrated an extension of median overall survival (OS) of~2-5 months [2] [3] [4] [5] [6] [7] [8] [9] . Notably, recent retrospective investigations suggest a high prevalence of cross-resistance between these agents [1] . Moreover, the optimal first-line therapy and sequencing of these agents is unclear [1] .
Randomized trials have not compared the outcomes of patients receiving first-line chemotherapy vs antiandrogen therapy for mCRPC. Given that randomized trials are unlikely to definitively address this issue, large retrospective studies of individual-level real-world data are needed to provide insights into how the optimal first-line therapy may be determined. In the present study, we used the Veterans Health Administration (VHA) dataset to compare real-world patient outcomes after first-line taxane-based chemotherapy vs antiandrogen therapy in patients with mCRPC, after accounting for known clinical and laboratory prognostic factors.
Patients and Methods

Study Design and Cohort Assignments
Patient data (baseline characteristics and treatment patterns) were obtained from the VHA medical dataset. Eligible patients had ≥1 medical claim with a diagnosis of prostate cancer, and initiated first-line therapy for mCRPC consisting of antiandrogen therapy (abiraterone, enzalutamide) or taxane-based chemotherapy (docetaxel, cabazitaxel) between 1 October 2012 and 30 September 2014 (defined as the index date). Patients were required to have continuous health plan enrolment for ≥24 months before the index date. Patient claims were examined until death or 30 September 2015 (the data cut-off date), whichever occurred first. Patients were required to receive prior androgen deprivation therapy (ADT) during the pre-index period, but were excluded if the first recorded ADT occurred within the first 6 months of the preindex period (wash-out period). This was done to optimally capture duration of prior ADT and select for patients who newly initiated ADT alone for castration-sensitive disease and to exclude ADT carryover from prior use. Patients were grouped into antiandrogen therapy and chemotherapy cohorts based on the index drug identified (abiraterone or enzalutamide for antiandrogen therapy; docetaxel for chemotherapy) and stratified by duration of prior ADT.
Definitions of Collected Variables
All outcomes were measured during the follow-up period, inclusive of the index date (Fig. S1 ). Sociodemographic variables (age, race, length of follow-up period) were measured on the index date. ADT treatment duration was counted until the index date. The time to discontinuation of antiandrogen therapy or chemotherapy was calculated until drug discontinuation or initiation of a new drug, whichever occurred earlier. A continuous gap of ≥60 days after initiating chemotherapy or antiandrogen therapy was defined as discontinuation, and time to discontinuation was calculated accordingly. A treatment-free interval was defined as the number of days from the end of first-line treatment to the start of second-line treatment for mCRPC.
A PSA response was defined as a ≥50% reduction from baseline PSA level. Baseline value was defined by using the PSA value within 3 months before and closest to the index date. PSA progression was defined as a ≥25% increase and an absolute increase of ≥2 ng/mL from the PSA nadir. When there was no decrease in the PSA value from baseline, PSA progression was defined as a ≥25% increase from the baseline value, with an increase in the absolute value of ≥2 ng/mL after 12 weeks of treatment. Survival was calculated as the total number of days from the index date to the death date. The percentage of patients who died after antiandrogen therapy or chemotherapy therapy during the follow-up period was reported as the death rate.
Statistical Considerations
Demographic and baseline characteristics and outcome measures including age, race, comorbidities, time to first-line discontinuation, treatment-free interval, PSA-related outcomes, OS and prior ADT treatment duration (above/ below median) were reported for the overall population, and differences between groups based on type of therapy (antiandrogen therapy vs chemotherapy) were reported. Numbers and percentages were calculated for dichotomous and polychotomous variables. Mean and standard deviation were calculated for continuous variables.
A chi-squared test was used to evaluate the statistical significance of differences in categorical variables, while Student's t-test was used for the mean of continuous variables. The difference between the groups was considered statistically significant at P values <0.05. In addition to P values, standardized differences were calculated for each variable and the difference between the groups was considered as practically significant at a standardized difference <10%.
All significant covariates from the univariate analysis were included in the multivariate Cox proportional hazards model. Analysis was adjusted for age, prior ADT duration (above/ below median), known and available data for prognostic factors (haemoglobin, albumin, alkaline phosphatase [ALP], PSA), Charlson comorbidity index (CCI), chronic disease score (CDS) and use of narcotic analgesics. Univariate analysis was performed to assess the association of the abovementioned independent variables with time to discontinuation and OS. Multivariate Cox regression models adjusting for relevant covariates were used to compare OS and time to discontinuation outcomes between chemotherapy and antiandrogen therapy cohorts.
The results were further confirmed by propensity score estimation with a multivariable logistic regression model, where treatment assignment to antiandrogen therapy or chemotherapy was regressed on the key prognostic variables: age, CCI score, CDS, duration of prior ADT treatment, PSA concentration ≥ median, haemoglobin concentration < lower limit of normal (LLN), albumin concentration < LLN and lactase dehydrogenase (LDH) concentration ≥ upper limit of normal (ULN). Patients were classified into quintiles based 872 © 2018 The Authors BJU International © 2018 BJU International on their propensity scores. A Cox proportional hazards model was estimated within each propensity score quintile stratum; the hazard ratios (HRs) from each stratum were then combined into a summary estimate using the propensity quintile as the stratifying variable in PROC PHREG procedure.
Results
Patient Population and Therapy Received
The overall sample size was 1445 patients with mCRPC, which included 1108 patients in the antiandrogen therapy cohort and 337 patients in the chemotherapy cohort (Fig. S2 ). In the antiandrogen therapy cohort, 996 patients received abiraterone and 112 patients received enzalutamide as firstline therapy. In the chemotherapy cohort, all 337 patients were prescribed docetaxel, and none were prescribed cabazitaxel. Second-line therapies for each cohort are shown in Fig. S2 .
Baseline Patient Characteristics
Compared with the chemotherapy (docetaxel) cohort, patients in the antiandrogen therapy cohort were older (median 77.0 vs 67.0 years; P < 0.001). There were significantly more white patients (70.3% vs 62.9%; P = 0.010) and significantly fewer black patients (20.4% vs 26.1%; P = 0.026) in the antiandrogen therapy cohort than in the chemotherapy cohort. The antiandrogen therapy cohort had a significantly lower proportion of patients who had other treatments after the index time, including radiation (7.3% vs 13.4%; P < 0.001) and narcotic analgesics (56.6% vs 79.8%; P < 0.001) compared with the chemotherapy cohort. Patients in the chemotherapy cohort had a higher CDS than in the antiandrogen therapy cohort (8.22 vs 7.44; P = 0.001 [ Table 1 ]). The median PSA was 53.62 ng/mL for all patients, and there were no differences between the antiandrogen therapy and chemotherapy cohorts. There were no significant differences in the haemoglobin and albumin values between antiandrogen therapy and chemotherapy cohorts; the median ALP was higher in the chemotherapy vs antiandrogen therapy cohort (109.00 vs 133.00 U/L, respectively; P = 0.019). The median duration of prior ADT was 464 days for all patients. Prior median ADT duration was significantly longer for patients in the antiandrogen therapy cohort than in the chemotherapy [docetaxel] cohort (485 vs 421 days; P < 0.001). Differences between the chemotherapy and antiandrogen therapy groups based on duration of prior ADT are shown in Table S1 .
Association of Variables with Overall Survival
Using multivariable analysis after controlling for prognostic factors, there was no difference in terms of OS between the chemotherapy and antiandrogen therapy cohorts (HR 1.041, 95% CI 0.853-1.270; P = 0.694). Kaplan-Meier survival difference was not significant (P = 0.067; Fig. 1A) . After applying the propensity score analysis, the HR for chemotherapy vs antiandrogen therapy was 1.047 (95% CI 0.861-1.273; P = 0.644 [ Table 2 ]). The following were associated with shorter OS: prior ADT duration < median; higher CCI; higher CDS; PSA concentration ≥ median; haemoglobin concentration < LLN; albumin concentration < LLN; and ALP concentration ≥ ULN (Table 3 ).
In the antiandrogen therapy cohort, longer duration of prior ADT was associated with longer OS (HR 0.566, 95% CI 0.464-0.690; P < 0.001 [ Fig. 1B] ). By contrast, prior ADT duration was not associated with OS in the chemotherapy cohort (HR 0.766, 95% CI 0.546-1.075; P = 0.123 [Table 3 and Fig. 1C] ). In the antiandrogen therapy cohort, PSA concentration ≥ median, haemoglobin concentration < LLN, albumin concentration < LLN and ALP concentration ≥ ULN were associated with shorter OS. In the chemotherapy (docetaxel) cohort, albumin concentration < LLN and ALP concentration ≥ ULN were predictive of shorter OS (Table 3) . Among patients within groups with prior ADT duration ≤ median and > median, antiandrogen therapy or chemotherapy treatment was not independently predictive of survival, while many of the other candidate factors were associated with survival (Table S2) .
Association of Variables with Time to Treatment Discontinuation
Time to discontinuation was shorter for chemotherapy vs antiandrogen therapy (HR 2.339, 95% CI 1.969-2.779; P < 0.001); however, reasons for discontinuation were unavailable, and may have included patient decision, toxicity, progression or death (Table 4) . PSA concentration ≥ median, prior ADT duration > median and ALP concentration ≥ ULN were associated with shorter time to discontinuation (Table 4) . PSA concentration ≥ median and prior ADT duration < median were associated with shorter time to discontinuation in the antiandrogen therapy cohort, but not in the chemotherapy cohort (Table 4) . 
PSA Response and Progression
In the total patient population, there was no significant difference in the proportion of patients with PSA response or PSA progression in the antiandrogen therapy vs the chemotherapy cohort. In the subset of patients with ADT duration ≤ median, significantly more patients had a PSA response in the chemotherapy cohort than in the antiandrogen therapy cohort (61.5% vs 51.1%; P = 0.024). Compared with the chemotherapy cohort, the antiandrogen therapy cohort had a significantly longer time to PSA progression (median time to PSA progression was 130.5 days for antiandrogen therapy and 112.0 days for chemotherapy; P = 0.001). These differences were observed in the subsets of patients with ADT ≤ or > median (Table S3) .
Treatment-Free Interval
The antiandrogen therapy cohort had a significantly lower proportion of patients who had second-line therapy (46.75% vs 65.28%; P < 0.001) and significantly longer time to secondline therapy from the index date (283 vs 191 days; P < 0.001) compared with the chemotherapy (docetaxel) cohort (Table S4 ). The antiandrogen therapy cohort also had a significantly lower proportion of patients with second-line abiraterone and second-line cabazitaxel. The treatment-free interval after discontinuation of first-line therapy was longer for the chemotherapy vs the antiandrogen therapy cohort (mean: 53 vs 39 days; P = 0.030; median: 1 vs 22 days; P < 0.001 [ Table S4] ). There was no significant difference in the duration of second-line treatments between cohorts.
Discussion
Research comparing antiandrogen therapy (abiraterone or enzalutamide) with taxane chemotherapy as first-line therapy for patients with mCRPC is limited, and randomized prospective trials are unlikely to be conducted. To our knowledge, the present retrospective study of 1445 patients in the VHA dataset is one of the largest studies comparing firstline antiandrogen therapy with chemotherapy for mCRPC with respect to patient outcomes of antiandrogen therapy at the individual patient level. Our retrospective analysis showed that the duration of OS was similar for both first-line antiandrogen therapy and chemotherapy, after controlling for known prognostic factors, in both multivariable and propensity score-based analysis.
Previous retrospective studies suggest that longer duration of prior ADT may be associated with greater benefit from abiraterone [10, 11] . Another retrospective study reported that short duration of prior ADT predicted poor outcomes with secondary hormonal therapy, but did not adversely affect outcomes with docetaxel [12] . Notably, in the present study, prior ADT duration > median was associated with longer OS and time to discontinuation in the antiandrogen therapy cohort but not in the chemotherapy cohort. Conversely, ADT duration ≤ median was associated with higher PSA response rate in the chemotherapy vs antiandrogen therapy cohort. Although these results require further validation, they suggest that the duration of ADT may be used to guide the physician's decision to prescribe chemotherapy or antiandrogen therapy, with longer prior ADT duration suggesting greater benefit from antiandrogen therapy vs chemotherapy, and vice versa. Our analysis confirmed that age, PSA, haemoglobin, ALP and albumin levels, CCI and CDS are prognostic for OS [13, 14] . Other known prognostic factors, such as LDH, visceral or liver metastases, circulating tumour cell count, performance status and Gleason score [13] [14] [15] [16] were not included in the present analysis because they were not readily available in the VHA database.
A retrospective study of 350 post-docetaxel patients with mCRPC suggested that longer OS may be associated with the cabazitaxel followed by abiraterone sequence [17] . Some studies have suggested that cross-resistance between sequential abiraterone, enzalutamide and docetaxel may be more pronounced than between antiandrogen therapy and CI, confidence interval; HR, hazard ratio. Variables included in the propensity score estimation: age, Charlson comorbidity index score, chronic disease score, duration of androgen deprivation therapy, PSA ≥ median, haemoglobin < lower limit of normal (LLN), albumin < LLN, lactase dehydrogenase ≥ upper limit of normal. *Denotes significant P value.
© 2018 The Authors BJU International © 2018 BJU International 875 Table 3 Multivariable Cox proportional hazards model for overall survival: all patients and index drug treatment cohorts. cabazitaxel [18] [19] [20] [21] . In the context of the CHAARTED, LATITUDE and STAMPEDE trials, which will probably lead to frequent administration of docetaxel or abiraterone in patients with metastatic or high-risk non-metastatic castration-sensitive disease [22] [23] [24] [25] , one concern is the development of resistance to docetaxel and antiandrogen therapy [26] . This warrants further investigation of cabazitaxel and other novel agents and combinations as firstline therapy for patients with mCRPC previously exposed to docetaxel or abiraterone in the castration-sensitive phase of the disease.
In the present analysis, patients receiving antiandrogen therapy had significantly longer treatment duration, time to PSA progression and shorter treatment-free interval after discontinuation compared with patients receiving chemotherapy. These results may be reflective of the fact that antiandrogen therapy is generally given continuously until disease progression, whereas chemotherapy is discontinued after a finite number of, generally, 8-10 cycles of therapy. Therefore, although antiandrogen therapy may be perceived as more convenient and less toxic, patients may benefit from the longer treatment-free interval after discontinuing chemotherapy. Interestingly, a larger proportion of patients received second-line therapy after first-line chemotherapy compared with first-line antiandrogen therapy. These data are consistent with previously reported studies, and suggest that the sequence of chemotherapy followed by antiandrogen therapy may be more feasible than the reverse sequence, probably because of the narrower therapeutic window of opportunity to deliver chemotherapy [17] .
The study has several limitations attributable to its retrospective design and the retrospectively assembled database. Clinical conditions were identified using International Classification of Diseases Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes, which are subject to potential miscoding. The presence of a claim for a filled prescription does not indicate whether the medication was consumed or taken as prescribed. Medications filled over the counter or provided as samples by the physician are not observed in the claims data. Additionally, given that outcomes and exposure are defined using administrative claims data, there is an inherent risk of information bias resulting from classification error. Selection bias may occur with the requirement that all patients have continuous enrolment during the financial year. Because of the retrospective nature of the study, the results are inherently limited and there probably is confounding by unobserved clinical or other criteria used to select patients for antiandrogen therapy vs chemotherapy. The baseline PSA value used was the PSA concentration 3 months before and closest to the index date; however, the patients were mostly treated off-trial and there was no mandated PSA immediately preceding therapy or at periodic intervals during treatment. ADT, androgen deprivation therapy; ALP, alkaline phosphatase; CDS, chronic disease score; HR, hazard ratio; LLN, lower limit of normal; ULN, upper limit of normal. *Denotes significant P-value.
Hence, PSA response and time to PSA progression may have been suboptimally captured.
The major advantage of the VHA dataset lies in it being the largest integrated healthcare system in the USA, which is used by a relatively homogeneous population. The dataset contains detailed inpatient and outpatient data, including demographic characteristics, details of laboratory tests, prescriptions and cost accounting. The stability of VHA data sources allows the superior analysis of the continuity of care of patients over multiple years [27] .
These results are hypothesis-generating, and prospective validation is required. Currently, the selection of patients for first-line antiandrogen therapy or chemotherapy is based on patient preferences, performance status, comorbidities and financial concerns. Other factors are emerging that could be considered in this context; indeed, preliminary data indicate that androgen receptor splice variants may be associated with resistance to antiandrogen therapy, but have no impact on the efficacy of chemotherapy [28] [29] [30] . Based on the results of the present study, the duration of prior ADT can also be used to guide patient selection. Further research needs to be conducted to observe treatment patterns and OS among patients with mCRPC receiving antiandrogen therapy vs chemotherapy. Translational research to identify molecular predictive biomarkers to advance precision medicine is critically important.
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